Brevipil Oral Syrup 200ml is an antiepileptic medicine designed to manage partial-onset seizures in individuals with epilepsy. It is a next-generation anticonvulsant belonging to the pyrrolidone class, working effectively by binding to the synaptic vesicle protein 2A (SV2A) in the brain. This selective binding helps reduce excessive neuronal firing, stabilizing electrical activity and preventing seizures.

This formulation is available both as oral syrup and injectable solution, offering flexibility in administration for different patient needs. The syrup form is especially beneficial for children, elderly patients, or those who have difficulty swallowing tablets, while the injection form is used for rapid control of seizures in emergency settings or when oral intake isn’t possible.

Brevipil Oral Syrup 200ml offers fast absorption and high brain penetration, providing quick relief and long-lasting control. It has been clinically proven to reduce seizure frequency with minimal behavioral or psychiatric side effects, making it a preferred alternative to older anticonvulsants such as levetiracetam.